UB Paderborn / Katalog / Suche / in CDI

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Molecular metabolism (Germany), 2018-12, Vol.18, p.3-14

2018

Link zum Volltext

Verfügbarkeit prüfen

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell metabolism, 2022-09, Vol.34 (9), p.1234-1247.e9

2022

Link zum Volltext

Verfügbarkeit prüfen

Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

eLife, 2016-04, Vol.5

2016

Link zum Volltext

Verfügbarkeit prüfen

734-P: Cellular Internalization and Localization of Once-Weekly Basal Insulin Fc (BIF)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.1080-1090

2023

Link zum Volltext

Verfügbarkeit prüfen

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

Endocrine reviews, 2024-05, Vol.45 (3), p.379-413

2024

Link zum Volltext

Verfügbarkeit prüfen

1588-P: Translatable Modeling of Glucagon Actions in Human iPSC-Derived Hepatocytes Uniquely Predicts Differential Clinical Responses to Glucagon Analog Agonist Molecules

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry

The FEBS journal, 2022-05, Vol.289 (9), p.2657-2671

2022

Link zum Volltext

Verfügbarkeit prüfen

Structural determinants of dual incretin receptor agonism by tirzepatide

Proceedings of the National Academy of Sciences - PNAS, 2022-03, Vol.119 (13), p.e2116506119-e2116506119

2022

Link zum Volltext

Verfügbarkeit prüfen

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

The Journal of clinical investigation, 2021-06, Vol.131 (12), p.1-14

2021

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors

Journal of medicinal chemistry, 2022-10, Vol.65 (20), p.13892-13909

2022

Link zum Volltext

Verfügbarkeit prüfen

682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

FGF-21 as a novel metabolic regulator

The Journal of clinical investigation, 2005-06, Vol.115 (6), p.1627-1635

2005

Link zum Volltext

Verfügbarkeit prüfen

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Internalization and localization of basal insulin peglispro in cells

Molecular and cellular endocrinology, 2017-10, Vol.454, p.23-38

2017

Link zum Volltext

Verfügbarkeit prüfen

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

The Journal of pharmacology and experimental therapeutics, 2016-06, Vol.357 (3), p.459

2016

Link zum Volltext

Verfügbarkeit prüfen

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union

Regulatory toxicology and pharmacology, 2017-08, Vol.88, p.56-65

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

The Journal of clinical investigation, 2004-06, Vol.113 (11), p.1571-1581

2004

Link zum Volltext

Verfügbarkeit prüfen

Glucagon as a target for the treatment of Type 2 diabetes

Expert opinion on therapeutic targets, 2005-06, Vol.9 (3), p.593-600

2005

Link zum Volltext

Verfügbarkeit prüfen

Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and Nm23

Cancer research (Chicago, Ill.), 2001-03, Vol.61 (5), p.2071-2079

2001

Link zum Volltext

Verfügbarkeit prüfen

Interaction of the Ras-Related Protein Associated with Diabetes Rad and the Putative Tumor Metastasis Suppressor NM23 Provides a Novel Mechanism of GTPase Regulation

Proceedings of the National Academy of Sciences - PNAS, 1999-12, Vol.96 (26), p.14911-14918

1999

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of Rad Inhibits Glucose Uptake in Cultured Muscle and Fat Cells

The Journal of biological chemistry, 1996-09, Vol.271 (38), p.23111-23116

1996

Link zum Volltext

Verfügbarkeit prüfen

Rad and Rad-related GTPases Interact with Calmodulin and Calmodulin-dependent Protein Kinase II

The Journal of biological chemistry, 1997-05, Vol.272 (18), p.11832-11839

1997

Link zum Volltext

Verfügbarkeit prüfen

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

Journal of cellular physiology, 2008-04, Vol.215 (1), p.1-7

2008

Link zum Volltext

Verfügbarkeit prüfen

Structure Based Design of Active Site-Directed, Highly Potent, Selective, and Orally Bioavailable LMW-PTP Inhibitors

Journal of medicinal chemistry, 2022-10, Vol.65 (20), p.13892-13909

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

734-P: Cellular Internalization and Localization of Once-Weekly Basal Insulin Fc (BIF)

Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

1588-P: Translatable Modeling of Glucagon Actions in Human iPSC-Derived Hepatocytes Uniquely Predicts Differential Clinical Responses to Glucagon Analog Agonist Molecules

Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry

Structural determinants of dual incretin receptor agonism by tirzepatide

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors

682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice

FGF-21 as a novel metabolic regulator

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

Internalization and localization of basal insulin peglispro in cells

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Glucagon as a target for the treatment of Type 2 diabetes

Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and Nm23

Interaction of the Ras-Related Protein Associated with Diabetes Rad and the Putative Tumor Metastasis Suppressor NM23 Provides a Novel Mechanism of GTPase Regulation

Overexpression of Rad Inhibits Glucose Uptake in Cultured Muscle and Fat Cells

Rad and Rad-related GTPases Interact with Calmodulin and Calmodulin-dependent Protein Kinase II

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

Structure Based Design of Active Site-Directed, Highly Potent, Selective, and Orally Bioavailable LMW-PTP Inhibitors

Suchergebnisse filtern